AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...

AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in NEJM...

AstraZeneca plans $1.5 billion ADC manufacturing facility in Singapore, boosting global supply of cancer treatments. Learn more about this greenfield investment...

AstraZeneca's sipavibart shows promising results in Phase III COVID-19 prevention trial for immunocompromised patients, reducing symptomatic cases significantly. A potential game-changer in protecting vulnerable populations...

AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...

AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...